Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim
Boehringer Ingelheim
4 Nov 2026: Trial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 4 Nov 2026
- Title
- A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
- Conditions
- Bronchiectasis
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Kazakhstan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Romania, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom
- Country
- United States
- Reference
- NCT07915219
- Location
- United States, Argentina, Austria
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Boehringer Ingelheim
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Boehringer Ingelheim in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.